Discontinued — last reported Q2 '24

Non-Current Assets

AFS Securities

Bristol-Myers Squibb AFS Securities increased by 17.3% to $406.00M in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 25.3%, from $324.00M to $406.00M.

Analysis

StatementBalance Sheet Statement
SectionNon-Current Assets
CategoryCapital Allocation
SignalContext dependent
VolatilityModerate
First reportedQ1 2021
Last reportedQ2 2024

How to read this metric

An increase reflects capital allocation toward investment portfolios, while a decrease may signal portfolio rebalancing or asset liquidation.

Detailed definition

Available-for-sale securities are debt or equity investments that are not classified as trading or held-to-maturity, and...

Peer comparison

Common in the investment portfolios of banks and insurance companies.

Metric ID: fin_afs_securities

Historical Data

9 periods
 Q4 '22Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25
Value$0.00$364.00M$367.00M$357.00M$324.00M$320.00M$344.00M$346.00M$406.00M
QoQ Change+0.8%-2.7%-9.2%-1.2%+7.5%+0.6%+17.3%
YoY Change-12.1%-6.3%-3.1%+25.3%
Range$0.00$406.00M
Avg YoY Growth+1.0%
Median YoY Growth-4.7%
Current Streak3 quarters growth

Frequently Asked Questions

What is Bristol-Myers Squibb's afs securities?
Bristol-Myers Squibb (BMY) reported afs securities of $406.00M in Q3 2025.
How has Bristol-Myers Squibb's afs securities changed year-over-year?
Bristol-Myers Squibb's afs securities increased by 25.3% year-over-year, from $324.00M to $406.00M.
What does afs securities mean?
Investments in securities that are held for potential sale and marked to fair market value.

Cookie Preferences

We use cookies for analytics. See our Privacy and Cookie Policy.